Welcome to our dedicated page for Envveno Medical Corporation news (Ticker: NVNO), a resource for investors and traders seeking the latest updates and insights on Envveno Medical Corporation stock.
enVVeno Medical Corporation (NASDAQ: NVNO) is an Irvine, California-based, late clinical-stage medical device company developing bioprosthetic, tissue-based venous valves for deep venous disease. This news page aggregates company announcements, press releases, and market disclosures related to enVVeno’s clinical programs, regulatory interactions, and corporate actions.
Readers can follow updates on VenoValve®, enVVeno’s first-in-class surgical replacement venous valve for severe deep chronic venous insufficiency and deep venous insufficiency, as well as enVVe®, its non-surgical, transcatheter-based replacement venous valve for deep venous CVI. News items include information on pivotal clinical studies, health economic analyses, and the company’s discussions with the U.S. Food & Drug Administration, such as the not-approvable letter for the VenoValve PMA application and the subsequent supervisory appeal process.
In addition to clinical and regulatory developments, this feed covers financial and corporate news, including quarterly financial updates, capital-raising arrangements like the at-the-market equity program, and shareholder matters disclosed in proxy statements and Form 8-K filings. Announcements about investor presentations, virtual investor segments, and other outreach events featuring enVVeno’s leadership are also reflected here.
For investors and observers tracking NVNO, the news page offers a centralized view of how enVVeno is progressing its venous valve technologies, responding to regulatory feedback, and managing its capital structure through actions such as a board-approved reverse stock split. Regularly reviewing this page can help users understand the evolving context around enVVeno’s development pipeline, regulatory milestones, and key corporate decisions.
enVVeno Medical Corporation announced the issuance of U.S. Patent No. 11,285,243 for the VenoValve, a potential first-in-class treatment for Chronic Venous Insufficiency (CVI). The VenoValve is currently under evaluation in the SAVVE U.S. pivotal trial across major hospitals, addressing a significant unmet medical need for the 2.4 million U.S. patients suffering from deep venous CVI. The patent covers the manufacturing method of the valve's tissue component, enhancing protection for enVVeno's leading product and representing a significant step in its patent strategy.
enVVeno Medical Corporation (NASDAQ: NVNO) announced a strong cash position of $55 million, expected to fund operations through the end of 2024. The company has completed 9 VenoValve surgeries and has 16 clinical sites active in its pivotal SAVVE trial. The VenoValve's long-term safety and efficacy data were presented at a prominent medical meeting, and the company has also received ISO 13485 certification, aiding its commercialization efforts. Despite reporting a net loss of $16.5 million for 2021, cash reserves allow for focused execution of clinical trials.
enVVeno Medical Corporation (NASDAQ: NVNO) announced positive results from its first-in-human study of the VenoValve, showing sustained safety and effectiveness one year post-implantation. The study included 11 patients with severe deep venous Chronic Venous Insufficiency (CVI), revealing a 54% improvement in reflux, 56% in disease manifestations, and 76% in pain. The VenoValve aims to address the shortcomings of existing treatments and is currently under evaluation in the ongoing SAVVE U.S pivotal trial, having received Breakthrough Device Designation from the FDA.
enVVeno Medical Corporation (NASDAQ:NVNO) reported favorable thirty-month outcomes for its VenoValve in first-in-human trials, presented at the 34th Annual Meeting of the American Venous Forum. Key findings include no relapses of Chronic Venous Insufficiency (CVI) or venous ulcers, with significant improvements in reflux (55%), CVI disease manifestations (61%), and pain (81%). The CEO expressed optimism about ongoing trials that may lead to further advancements in treating CVI. As the company gears up for pivotal trials, data showcasing effective solutions for CVI patients continues to grow.
Summary not available.
enVVeno Medical Corporation (NASDAQ:NVNO) will present at the Virtual Investor 2022 Top Picks Conference on January 25, 2022, at 1:00 PM ET. CEO Robert Berman will lead the presentation, which includes a corporate overview and an interactive Q&A session. Investors can submit questions live or in advance through the conference website. A live video webcast will be available on the Company’s Events page, with a replay accessible for one year. enVVeno focuses on innovative treatments for venous disease, including its lead product, the VenoValve.
enVVeno Medical Corporation (Nasdaq: NVNO) will host a Virtual Investor Roundtable Event on November 16, 2021, at 1:00 PM ET, featuring CEO Robert Berman and Chief Medical Officer Marc Glickman, M.D. The session will include a presentation, a moderated discussion, and a live Q&A segment.
Investors can submit questions in advance or during the event. A live video webcast will be available on the Company's website, with a replay accessible for one year following the presentation.
enVVeno Medical Corporation (NASDAQ: NVNO) announced its third-quarter 2021 financial results, highlighting a net loss of $2.4 million, reflecting a 21% increase in losses year-over-year. The company successfully completed the first VenoValve surgery in the pivotal SAVVE trial, aimed at treating severe deep venous Chronic Venous Insufficiency (CVI). A recent $20 million direct offering strengthened its cash position, ending the quarter with $57.9 million in cash. The trial expects to enroll up to 75 patients across multiple centers, with topline data anticipated by late 2022.
enVVeno Medical Corporation (NASDAQ:NVNO) announced the successful completion of the first VenoValve surgery in its SAVVE U.S. pivotal trial, aimed at addressing severe chronic venous insufficiency (CVI) affecting 2.4 million patients in the U.S. The procedure was performed by Dr. Adriana Laser, marking a significant milestone for the company. The trial aims to enroll 75 patients across 20 centers, with expected efficacy data by the end of 2022. The VenoValve seeks to restore proper blood flow and provides a potential treatment for patients with deep vein CVI, for which there are currently no effective options.
enVVeno Medical Corporation (NASDAQ:NVNO) has successfully completed its rebranding and is now trading under the ticker symbol NVNO. Formerly known as Hancock Jaffe Laboratories, the company focuses on innovative bioprosthetic solutions for venous disease treatment. The lead product, VenoValve, aims to address deep venous Chronic Venous Insufficiency (CVI), impacting over 2.4 million people in the U.S. The device is under evaluation in the SAVVE pivotal study, with data anticipated in late 2022.